Tumorigenic transformation of human prostatic epithelial cell line RWPE-1 by growth hormone-releasing hormone (GHRH)

  • Prostate. 2022 Jun;82(8):933-941. doi: 10.1002/pros.24339.
Laura Muñoz-Moreno  1 ,  M José Carmena  1 ,  Juan C Prieto  1 ,  Andrew V Schally  2  3  4 ,  Ana M Bajo  1
Affiliations
  • 1. Grupo de Investigación Cánceres de Origen Epitelial, Área de Bioquímica y Biología Molecular, Departamento de Biología de Sistemas, Facultad de Medicina y Ciencias de la Salud, Universidad de Alcalá, Alcalá de Henares, Madrid, Spain.
  • 2. Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center, Miami, Florida, USA.
  • 3. Division of Hematology/Oncology, Departments of Pathology and Medicine, Miller School of Medicine, University of Miami, Miami, Florida, USA.
  • 4. Department of Medicine, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, Florida, USA.
Abstract

Background: Growth hormone-releasing hormone (GHRH) and its receptors have been implicated in the progression of various Tumors. In this study, we analyzed the carcinogenetic potential of exposure to GHRH of a nontumor human prostate epithelial cell line (RWPE-1) as well as its transforming effect in a xenograft model.

Methods: We performed cell viability, cell proliferation, adhesion and migration assays. In addition, metalloprotease (MMP)-2 activity by means gelatin zymography, GHRH-R subcellular location using confocal immunofluorescence microscopy and vascular endothelial growth factor (VEGF) levels by enzyme-linked Immunoassay were assessed. Besides, we developed an in vivo model in order vivo model to determine the role of GHRH on tumorigenic transformation of RWPE-1 cells.

Results: In cell cultures, we observed development of a migratory phenotype consistent with the gelatinolytic activity of MMP-2, expression of VEGF, as well as E-cadherin-mediated cell-cell adhesion and increased cell motility. Treatment with 0.1 µM GHRH for 24 h significantly increased cell viability and cell proliferation. Similar effects of GHRH were seen in RWPE-1 Tumors developed by subcutaneous injection of GHRH-treated cells in athymic nude mice, 49 days after inoculation.

Conclusions: Thus, GHRH appears to act as a cytokine in the transformation of RWPE-1 cells by mechanisms that likely involve epithelial-mesenchymal transition, thus reinforcing the role of GHRH in tumorigenesis of prostate.

Keywords
GHRH; RWPE-1 cells; epithelial-mesenchymal transition; prostate cancer; tumorigenesis.